Open, Non-comparative Pilot Study to Evaluate the Safety and Efficacy of Intraovarian Plasma Rich in Growth Factors (PRGF) in Patients With Low Ovarian Reserve
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Plasma Rich in Growth Factors (PRGF).
- Who it may be relevant to
- Registry conditions: Low Ovarian Reserve. Basic parameters: 18 years — 50 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Spain
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Open, Non-comparative, Pilot Study to Evaluate the Safety and Efficacy of Intraovarian Growth Factor-rich Plasma in Patients With Low Ovarian Reserve
Overview
The use of plasma rich in growth factors (PRGF) improves ovarian reserve markers and IVF laboratory parameters in women with low ovarian reserve. Primary objective To compare ovarian reserve markers and IVF-ICSI laboratory results before and after PRGF infusion. Secondary Objectives * To compare pre- and post-treatment pregnancy rates. * To collect complications associated with the application of intraovarian PRGF. General Outline of the Study VISIT 1 * Patient Selection * Confirm that he/she has all the analyses and variables to be studied. * Signing of Informed Consent * Usual IVF protocol (1st IVF cycle) VISIT 2 * Instillation of intraovarian PRGF on the day of the puncture of the 1st IVF cycle in the FJD VISIT 3 * Analytical control at 4 weeks VISIT 4 * Analytical control at 8 weeks VISIT 5 * In case of failure to achieve gestation Start of 2nd cycle of IVF
Interventions
- Biological Plasma Rich in Growth Factors (PRGF)
On the day of the ovarian puncture of the 1st IVF cycle, intraovarian instillation of plasma rich in growth factors will be performed.
Primary outcome measures
- Number of cycles cancelled pre-puncture [Time frame: Day 1]
- Ovarian reserve markers [Time frame: Day 1 vs visit 4 weeks]
- Number of cycles cancelled post-puncture [Time frame: visit 4 weeks and visit 8 weeks]
- Number of oocytes recovered [Time frame: visit 4 weeks and visit 8 weeks]
- Number of MII (metaphase II stage oocyte) on the day of the puncture [Time frame: visit 2, day of the puncture (from the first day of menstruation, approximately 22 days later)]
- Number of fertilised oocytes [Time frame: visit 4 weeks and visit 8 weeks]
- Number of embryos obtained per EOC (ovarian stimulation) cycle [Time frame: visit 4 weeks and visit 8 weeks]
- Number of embryos of good quality (A or B quality according to ASEBIR classification). [Time frame: visit 4 weeks and visit 8 weeks]
- Number of frozen embryos [Time frame: visit 4 weeks and visit 8 weeks]
Eligibility criteria
Inclusion criteria
- Women of childbearing age as defined by the CTFG\*.
- Women in group 3 and 4 of the POSEIDON classification for low reserve:
- POSEIDON 3: patients ˂ 35 years of age with decreased ovarian reserve (AMH <1.2 ng/ml, AFC <5).
- POSEIDON 4: patients ≥ 35 years with decreased ovarian reserve (AMH <1.2 ng/ml, AFC <5).
- Patients with at least one ovary.
- Infertility of more than 1 year duration.
- Provision of safe ovarian access on the day of the puncture.
- They agree to participate and to give their written consent.
Exclusion criteria
- Have a diagnosis of clinical ovarian insufficiency - Patients with an ongoing pregnancy - Patients with a clinical diagnosis of ovarian failure
- Patients with ongoing pregnancy
- Current or previous IgA deficiency,
- Ovarian failure secondary to identified genetic causes.
- Presence of pelvic adhesions after abdominal surgery.
- Chronic use of aspirin, NSAIDs or anticoagulants.
- Diseases that alter platelet number or function.
- Psychiatric disorder that precludes participation in the study (including active substance abuse or dependence).
- Obesity (BMI ≥ 30).
- Current female smokers (≥ 15 cigarettes per day) - Current smoking (≥ 15 cigarettes per day)
- Patients affected by neoplastic disease
- Severe male factor infertility
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
Spain · 1 center
- Hospital Universitario Fundación Jiménez Diaz — Madrid
Identifiers
NCT: NCT06975683 · URA-PRGF-01 · 2024-514444-87-00